07:16 AM EDT, 05/28/2025 (MT Newswires) -- InflaRx ( IFRX ) said Wednesday it plans to discontinue further development of vilobelimab for the treatment of pyoderma gangrenosum, a rare and inflammatory skin disease.

An independent data monitoring committee conducting an unblinded interim analysis for a phase 3 trial for vilobelimab recommended that the trial be stopped due to futility, the company said.

InflaRx ( IFRX ) said it intends to focus its resources on INF904, with phase 2a data readouts in chronic spontaneous urticaria and hidradenitis suppurativa expected this summer.

The company said it is also contemplating additional cost savings and redirection of resources, with a view to extending its existing cash runway

InflaRx ( IFRX ) shares were down nearly 51% in recent premarket activity.